<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:DOC-6HUGW64V</identifier><date>2015</date><creator>Hojs-Fabjan, Tanja</creator><relation>documents/doc/6/URN_NBN_SI_doc-6HUGW64V_001.pdf</relation><relation>documents/doc/6/URN_NBN_SI_doc-6HUGW64V_001.txt</relation><format format_type="issue">1</format><format format_type="volume">66</format><format format_type="type">article</format><format format_type="extent">str. 73-79</format><identifier identifier_type="ISSN">0014-8229</identifier><identifier identifier_type="COBISSID">5287743</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-6HUGW64V</identifier><language>slv</language><publisher>Slovensko farmacevtsko društvo</publisher><source>Farmacevtski vestnik</source><rights>InC</rights><subject language_type_id="slv">imunomodulatorna zdravila</subject><subject language_type_id="slv">multipla skleroza</subject><subject language_type_id="eng">therapy</subject><subject language_type_id="slv">zdravljenje</subject><title>Treatment of multiple sclerosis</title><title>Zdravljenje multiple skleroze</title></Record>